United States - English - NLM (National Library of Medicine)

camber pharmaceuticals, inc. - dabigatran etexilate mesylate (unii: sc7nuw5iit) (dabigatran - unii:i0vm4m70gc) - dabigatran etexilate capsules are indicated to reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation. dabigatran etexilate capsules are indicated for the treatment of deep venous thrombosis and pulmonary embolism in adult patients who have been treated with a parenteral anticoagulant for 5 to 10 days. dabigatran etexilate capsules are indicated to reduce the risk of recurrence of deep venous thrombosis and pulmonary embolism in adult patients who have been previously treated. pediatric use information is approved for boehringer ingelheim pharmaceuticals, inc.’s pradaxa (dabigatran etexilate) capsules. however, due to boehringer ingelheim pharmaceuticals, inc.’s marketing exclusivity rights, this drug product is not labeled with that information. dabigatran etexilate capsules are contraindicated in patients with: • active pathological bleeding [see warnings and precautions ( 5.2) and adverse reactions ( 6.1)] • history of a seri

United States - English - NLM (National Library of Medicine)

ascend laboratories, llc - dabigatran etexilate mesylate (unii: sc7nuw5iit) (dabigatran - unii:i0vm4m70gc) - dabigatran etexilate capsules is indicated to reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation. dabigatran etexilate capsules is indicated for the treatment of deep venous thrombosis and pulmonary embolism in adult patients who have been treated with a parenteral anticoagulant for 5 to 10 days.  dabigatran etexilate capsules is indicated to reduce the risk of recurrence of deep venous thrombosis and pulmonary embolism in adult patients who have been previously treated. dabigatran etexilate capsules is indicated for the prophylaxis of deep vein thrombosis and pulmonary embolism, in adult patients who have undergone hip replacement surgery.  pediatric use information is approved for boehringer ingelheim pharmaceuticals, inc.’s pradaxa (dabigatran etexilate) capsules. however, due to boehringer ingelheim pharmaceuticals, inc.’s marketing exclusivity rights, this drug product is not labeled with that information. dabigatran etexilate capsules is contraindic

United States - English - NLM (National Library of Medicine)

american health packaging - dabigatran etexilate mesylate (unii: sc7nuw5iit) (dabigatran - unii:i0vm4m70gc) - dabigatran etexilate capsules are indicated to reduce the risk of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation. dabigatran etexilate capsules are indicated for the treatment of deep venous thrombosis and pulmonary embolism in adult patients who have been treated with a parenteral anticoagulant for 5 to 10 days. dabigatran etexilate capsules are indicated to reduce the risk of recurrence of deep venous thrombosis and pulmonary embolism in adult patients who have been previously treated. pediatric use information is approved for boehringer ingelheim pharmaceuticals, inc.’s pradaxa (dabigatran etexilate) capsules. however, due to boehringer ingelheim pharmaceuticals, inc.’s marketing exclusivity rights, this drug product is not labeled with that information. dabigatran etexilate capsules are contraindicated in patients with: - active pathological bleeding [see warnings and precautions (5.2) and adverse reactions (6.1)] - history of a serious hypersensitivity

Ireland - English - HPRA (Health Products Regulatory Authority)

krka, d.d., novo mesto - dabigatran etexilate mesilate - capsule, hard - dabigatran etexilate

Ireland - English - HPRA (Health Products Regulatory Authority)

krka, d.d., novo mesto - dabigatran etexilate mesilate - capsule, hard - dabigatran etexilate

Ireland - English - HPRA (Health Products Regulatory Authority)

krka, d.d., novo mesto - dabigatran etexilate mesilate - capsule, hard - dabigatran etexilate

Israel - English - Ministry of Health

teva israel ltd - dabigatran etexilate as mesylate - capsules - dabigatran etexilate as mesylate 150 mg - dabigatran etexilate - prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation.treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults.

Israel - English - Ministry of Health

teva israel ltd - dabigatran etexilate as mesylate - capsules - dabigatran etexilate as mesylate 110 mg - dabigatran etexilate - primary prevention of venous thromboembolic events in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery.prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation.treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults

Israel - English - Ministry of Health

teva israel ltd - dabigatran etexilate as mesylate - capsules - dabigatran etexilate as mesylate 75 mg - dabigatran etexilate - primary prevention of venous thromboembolic events in adult patients who have undergone elective total hip replacement surgery or total knee replacement surgery

Malta - English - Medicines Authority

galenicum health, s.l. calle sant gabriel, 50 08950 esplugues de llobregat (barcelona) , spain - dabigatran etexilate - hard capsule - dabigatran etexilate 75 mg - antithrombotic agents